Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 7/20 | 0.68 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.68 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.68 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.68 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.68 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.68 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.68 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.68 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.68 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.68 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.68 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.46 |
| ▸ | BCL2L1 | Q07817 | 2/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.40 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.40 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17149287 | 0.86 | CYP2A6 (0.50) | HDAC1HDAC3HDAC4HDAC7HDAC2 | |
| SCHEMBL121300 | 0.84 | HDAC1 (0.70) | HDAC1HDAC3HDAC4HDAC7HDAC2 | |
| SCHEMBL24360345 | 0.82 | HDAC1 (0.68) | HDAC1HDAC3HDAC4HDAC7HDAC2 | |
| SCHEMBL10052926 | 0.81 | HDAC1 (1.00) | HDAC1HDAC3HDAC4HDAC7HDAC2 | |
| SCHEMBL2724666 | 0.80 | DHPS (0.47) | HDAC1HDAC3HDAC4HDAC7HDAC2 | |
| SCHEMBL31207866 | 0.79 | HDAC1 (0.69) | HDAC1HDAC3HDAC4HDAC7HDAC2 | |
| SCHEMBL2250510 | 0.79 | HDAC1 (0.69) | HDAC1HDAC3HDAC4HDAC7HDAC2 | |
| SCHEMBL464400 | 0.79 | HDAC1 (0.64) | HDAC1HDAC3HDAC4HDAC7HDAC2 | |
| SCHEMBL22479260 | 0.79 | LMNA (0.47) | HDAC1HDAC3HDAC4HDAC7HDAC2 | |
| SCHEMBL3064054 | 0.79 | CHRNA7 (0.45) | HDAC1HDAC3HDAC4HDAC7HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3233087-B1 | GEMINAL SUBSTITUTED QUINUCLIDINE AMIDE COMPOUNDS AS AGONISTS OF ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTORS | AXOVANT SCIENCES GMBH (DE) | 2019-10-02 | — | — | EP | disclosed |
| US-10183938-B2 | Geminal substituted quinuclidine amide compounds as agonists of α-7 nicotonic acetylcholine receptors | AXOVANT SCIENCES GMBH (CH) | 2019-01-22 | — | — | US | disclosed |
| US-20170369486-A1 | GEMINAL SUBSTITUTED QUINUCLIDINE AMIDE COMPOUNDS AS AGONISTS OF ALPHA-7 NICOTONIC ACETYLCHOLINE RECEPTORS | AXOVANT SCIENCES GMBH (CH) | 2017-12-28 | — | — | US | disclosed |
| US-8759533-B2 | Di-azetidinyl diamide as monoacylglcerol lipase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2014-06-24 | — | — | US | disclosed |
| US-8759333-B2 | Di-azetidinyl diamide as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2014-06-24 | — | — | US | disclosed |
| US-8637498-B2 | Oxopiperazine-azetidine amides and oxodiazepine-azetidine amides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2014-01-28 | — | — | US | disclosed |
| US-20130196969-A1 | DI-AZETIDINYL DIAMIDE AS MONOACYLGLCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA, NV (BE) | 2013-08-01 | — | — | US | disclosed |
| US-20130196968-A1 | DI-AZETIDINYL DIAMIDE AS MONOACYLGLCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA, NV (BE) | 2013-08-01 | — | — | US | disclosed |
| US-8431684-B2 | Process for the preparation of ibodutant (MEN15596) and related intermediates | MALESCI ISTITUTO FARMACOBIOLOGICO S.P.A. (IT) | 2013-04-30 | — | — | US | disclosed |
| US-8431684-B2 | Process for the preparation of ibodutant (MEN15596) and related intermediates | MALESCI ISTITUTO FARMACOBIOLOGICO S.P.A. (IT) | 2013-04-30 | — | — | US | disclosed |
| EP-2432778-B1 | PROCESS FOR THE PREPARATION OF IBODUTANT (MEN15596) AND RELATED INTERMEDIATES | MALESCI SAS (IT) | 2013-03-20 | — | — | EP | disclosed |
| US-20120077797-A1 | OXOPIPERAZINE-AZETIDINE AMIDES AND OXODIAZEPINE-AZETIDINE AMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2012-03-29 | — | — | US | disclosed |
| US-20120065370-A1 | PROCESS FOR THE PREPARATION OF IBODUTANT (MEN15596) AND RELATED INTERMEDIATES | MALESCI ISTITUTO FARMACOBIOLOGICO S.P.A. (IT) | 2012-03-15 | — | — | US | disclosed |
| US-20120065370-A1 | PROCESS FOR THE PREPARATION OF IBODUTANT (MEN15596) AND RELATED INTERMEDIATES | MALESCI ISTITUTO FARMACOBIOLOGICO S.P.A. (IT) | 2012-03-15 | — | — | US | disclosed |
| US-20120058986-A1 | DI-AZETIDINYL DIAMIDE AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-03-08 | — | — | US | disclosed |
| WO-2010133306-A1 | PROCESS FOR THE PREPARATION OF IBODUTANT (MEN15596) AND RELATED INTERMEDIATES | MALESCI ISTITUTO FARMACOBIOLOGICO S.P.A. (IT) | 2010-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065370-A1 | PROCESS FOR THE PREPARATION OF IBODUTANT (MEN15596) AND RELATED INTERMEDIATES | DDT, BBOX1, IMPDH2 | HDAC1 4611/4885HDAC3 4688/4885HDAC4 4854/4885 |
| US-20130196969-A1 | DI-AZETIDINYL DIAMIDE AS MONOACYLGLCEROL LIPASE INHIBITORS | MGLL, PNLIP, LPL | HDAC1 682/4885HDAC3 1589/4885HDAC4 2429/4885 |
| US-20120077797-A1 | OXOPIPERAZINE-AZETIDINE AMIDES AND OXODIAZEPINE-AZETIDINE AMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | LPL, PNLIP, LIPA | HDAC1 294/4885HDAC3 657/4885HDAC4 1474/4885 |
| US-20130196968-A1 | DI-AZETIDINYL DIAMIDE AS MONOACYLGLCEROL LIPASE INHIBITORS | MGLL, PNLIP, LPL | HDAC1 682/4885HDAC3 1589/4885HDAC4 2429/4885 |
| US-10183938-B2 | Geminal substituted quinuclidine amide compounds as agonists of α-7 nicotonic acetylcholine receptors | CHRNA7, CHRNA6, CHRNA5 | HDAC1 1669/4885HDAC3 2023/4885HDAC4 3260/4885 |
| US-20120058986-A1 | DI-AZETIDINYL DIAMIDE AS MONOACYLGLYCEROL LIPASE INHIBITORS | PNLIP, LPL, LIPA | HDAC1 1122/4885HDAC3 2416/4885HDAC4 3411/4885 |
| US-20170369486-A1 | GEMINAL SUBSTITUTED QUINUCLIDINE AMIDE COMPOUNDS AS AGONISTS OF ALPHA-7 NICOTONIC ACETYLCHOLINE RECEPTORS | CHRNA7, CHRNA6, CHRNA5 | HDAC1 1741/4885HDAC3 2160/4885HDAC4 3384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.